Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells

Urology
Akinori SatoTomohiko Asano

Abstract

To investigate the combined effect of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) and the protease inhibitor ritonavir on renal cancer cells. Renal cancer cells (769P, 786O, A498, ACHN, Caki-1) and renal proximal tubule epithelial cells were treated with SAHA (0-5 μM) with or without ritonavir (0-50 μM). Cell viability, clonogenecity, and changes in cell cycle were evaluated. The expression of acetylated histone, retinoblastoma protein (Rb), phosphorylated Rb, histone deacetylases, X-linked inhibitor of apoptosis, survivin, and active caspase 3 was assessed using Western blot analysis. SAHA induced histone acetylation and Rb dephosphorylation and inhibited cell growth in a time- and dose-dependent manner. SAHA and ritonavir combined inhibited cell proliferation effectively and promoted histone acetylation and Rb dephosphorylation but only slightly affected renal proximal tubule epithelial cell survival. The combination induced the accumulation of the sub-G(1) fraction, decreased the expression of X-linked inhibitor of apoptosis and survivin, and increased active caspase 3, thus inducing apoptosis. It also inhibited the expression of histone deacetylases. Combination therapy using SAHA and rit...Continue Reading

References

Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
May 29, 2000·Journal of Cellular Physiology·W D Cress, E Seto
Aug 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Jul 5, 2001·Cellular and Molecular Life Sciences : CMLS·S TimmermannA Harel-Bellan
May 2, 2003·Annals of the New York Academy of Sciences·Sam ThiagalingamJose F Ponte
Jan 22, 2004·Proceedings of the National Academy of Sciences of the United States of America·C-Y GuiP A Marks
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Purva BaliKapil Bhalla
Nov 18, 2005·Gene·Michele A GlozakEdward Seto
Feb 18, 2006·Nature Reviews. Drug Discovery·Christine B Yoo, Peter A Jones
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Mar 14, 2007·Apoptosis : an International Journal on Programmed Cell Death·S EmanueleG Tesoriere
Apr 22, 2008·Investigational New Drugs·Johan VansteenkistePatrick Schöffski
Jul 23, 2008·Molecular Cancer Therapeutics·Marianne KrausChristoph Driessen
Nov 1, 2008·International Journal of Cancer. Journal International Du Cancer·Md Zahidunnabi DewanNaoki Yamamoto
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thehang H LuuGeorge Somlo
Apr 7, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne M TraynorJoan H Schiller

❮ Previous
Next ❯

Citations

Oct 12, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Lauren L BrilliNeil A Hukriede
Oct 30, 2012·Molecular Oncology·Angela NebbiosoLucia Altucci
Dec 13, 2017·Archives of Pharmacal Research·Pusoon Chun
May 22, 2020·Seminars in Cancer Biology·Itishree KaushikSanjay K Srivastava

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.